Symptom Screen Plus CA125 Detects Early Ovarian Ca

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 7
Volume 17
Issue 7

Women’s reports of persistent, recent-onset symptoms linked to ovarian cancer-abdominal or pelvic pain, difficulty eating or feeling full quickly, and abdominal bloating-combined with CA125 testing may improve the early detection of ovarian cancer by 20%, according to Fred Hutchinson Cancer Research Center investigators (Cancer, published online June 23, 2008).

Women’s reports of persistent, recent-onset symptoms linked to ovarian cancer-abdominal or pelvic pain, difficulty eating or feeling full quickly, and abdominal bloating-combined with CA125 testing may improve the early detection of ovarian cancer by 20%, according to Fred Hutchinson Cancer Research Center investigators (Cancer, published online June 23, 2008).

The researchers gave a four-question symptom-screening questionnaire to 75 women about to undergo surgery for a pelvic mass who were later diagnosed with ovarian cancer (cases) and 254 healthy women at high risk for ovarian cancer (controls). The questionnaire and CA125 test used alone each detected about 50% of early-stage cases. Used together, the tests found 80.6% of early-stage cases, said M. Robyn Andersen, PhD, of the Public Health Sciences Division.

Related Videos
Interim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.
Treatment with mirvetuximab soravtansine appears to produce a 3-fold improvement in objective response rate vs chemotherapy among patients with folate receptor-α–expressing, platinum-resistant ovarian cancer in the phase 3 MIRASOL trial.
PRGN-3005 autologous UltraCAR-T cells appear well-tolerated and decreases tumor burden in a population of patients with advanced platinum-resistant ovarian cancer.
An expert from Dana-Farber Cancer Institute discusses findings from the final overall survival analysis of the phase 3 ENGOT-OV16/NOVA trial.